Regulatory role of resveratrol on Th17 in autoimmune disease

International Immunopharmacology

Volumn 11, Issue 3, 2011, Pages 310-318

  Petro, Thomas M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

EAE; Foxp3; IL 10; Multiple sclerosis; Resveratrol; Th17; Treg

Indexed keywords

INTERLEUKIN 10; RESVERATROL; TRANSCRIPTION FACTOR FOXP3;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; EFFECTOR CELL; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL;

EID: 79952101240     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.07.011     Document Type: Review

References (169)

1. Janeway Jr CA. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992;13:11-6.
2. Hengartner H, Odermatt B, Schneider R, Schreyer M, Walle G, MacDonald HR, et al. Deletion of self-reactive T cells before entry into the thymus medulla. Nature 1988;336:388-90.
3. Jenkinson EJ, Kingston R, Smith CA, Williams GT, Owen JJ. Antigen-induced apoptosis in developing T cells: a mechanism for negative selection of the T cell receptor repertoire. Eur J Immunol 1989;19:2175-7. (Pubitemid 20017730)
4. Shimon S, Noriko S, Jun S, Sayuri Y, Toshiko S, Misako I, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32.
5. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4 + CD25- naive T cells to CD4 + CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875-86. (Pubitemid 38032120)
6. Fu S, Zhang N, Yopp AC, Chen D, Mao M, Zhang H, et al. TGF-beta induces Foxp3+T-regulatory cells from CD4+CD25-precursors. Am J Transplant 2004;4:1614-27. (Pubitemid 39312295)
7. Hafler DA. Multiple sclerosis. J Clin Invest 2004;113:788-94. (Pubitemid 38544133)
8. Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009;8:244-53.
9. Talmadge JE, Singh R, Ageitos A, Buyukberber S. Potential for cytokine and product manipulation to improve the results of autologous stem cell transplantation for rheumatoid arthritis. J Rheumatol Suppl 2001;64:32-8. (Pubitemid 32946623)
10. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008;299:925-36. (Pubitemid 351397068)
11. Chan MM. Antimicrobial effect of resveratrol on dermatophytes and bacterial pathogens of the skin. Biochem Pharmacol 2002;63:99-104. (Pubitemid 34158808)
12. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-42.
13. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 2006;72:1439-52. (Pubitemid 44666744)
14. Lee KW, Lee HJ. The roles of polyphenols in cancer chemoprevention. Biofactors 2006;26:105-21.
15. Tredici G, Miloso M, Nicolini G, Galbiati S, Cavaletti G, Bertelli A. Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant? Drugs Exp Clin Res 1999;25:99-103.
16. Yoshida Y, Shioi T, Izumi T. Resveratrol ameliorates experimental autoimmune myocarditis. Circ J 2007;71:397-404. (Pubitemid 46409545)
17. Elmali N, Esenkaya I, Harma A, Ertem K, Turkoz Y, Mizrak B. Effect of resveratrol in experimental osteoarthritis in rabbits. Inflamm Res 2005;54:158-62. (Pubitemid 41178921)
18. Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation 2007;30:1-6. (Pubitemid 46438042)
19. Ma ZH, Ma QY, Wang LC, Sha HC, Wu SL, Zhang M. Effect of resveratrol on peritoneal macrophages in rats with severe acute pancreatitis. Inflamm Res 2005;54:522-7. (Pubitemid 43042240)
20. Shindler KS, Ventura E, Rex TS, Elliott P, Rostami A. SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 2007;48:3602-9. (Pubitemid 351261095)
21. Singh NP, Hegde V, Hofseth LJ, Nagarkatti M, Nagarkatti P. Resveratrol (trans-3, 5, 4'-trihydroxystilbene) ameliorates Experimental Allergic Encephalomyelitis (EAE) primarily via induction of apoptosis in t cells involving activation of AhR and ER. Mol Pharmacol 2007;72:508-21.
22. Imler Jr TJ, Petro TM. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17 + IL-10+ T cells, CD4- IFN-[gamma] + cells, and decreased macrophage IL-6 expression. Int Immunopharmacol 2009;9:134-43.
23. Rangachari M, Mauermann N, Marty RR, Dirnhofer S, Kurrer MO, Komnenovic V, et al. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med 2006;203:2009-19. (Pubitemid 44188474)
24. Sonderegger I, Rohn TA, Kurrer MO, Iezzi G, Zou Y, Kastelein RA, et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 2006;36:2849-56. (Pubitemid 44782558)
25. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-7. (Pubitemid 38032126)
26. Kim HR, Cho ML, Kim KW, Juhn JY, Hwang SY, Yoon CH, et al. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford) 2007;46:57-64.
27. Bao L, Lindgren JU, van der Meide P, Zhu S, Ljunggren HG, Zhu J. The critical role of IL-12p40 in initiating, enhancing, and perpetuating pathogenic events in murine experimental autoimmune neuritis. Brain Pathol 2002;12:420-9. (Pubitemid 35154929)
28. Gran B, Zhang GX, Yu S, Li J, Chen XH, Ventura ES, et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 2002;169:7104-10. (Pubitemid 36899299)
29. Gran B, Zhang GX, Rostami A. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit Rev Immunol 2004;24:111-28. (Pubitemid 39655089)
30. Becher B, Durell BG, Noelle RJ. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest 2003;112:1186-91. (Pubitemid 38056295)
31. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425:191-6. (Pubitemid 37150899)
32. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004;305:1010-3. (Pubitemid 39071777)
33. Imai S-i, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000;403: 795-800. (Pubitemid 30111843)
34. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004;305:390-2. (Pubitemid 38938153)
35. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004;23:2369-80. (Pubitemid 38954844)
36. Zhong M, Cheng GF, Wang WJ, Guo Y, Zhu XY, Zhang JT. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine 1999;6:79-84. (Pubitemid 129634463)
37. Gao X, Xu YX, Janakiraman N, Chapman RA, Gautam SC. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol 2001;62:1299-308. (Pubitemid 33055634)
38. Culpitt SV, Rogers DF, Fenwick PS, Shah P, De Matos C, Russell RE, et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 2003;58:942-6. (Pubitemid 37392803)
39. Frescas D, Valenti L, Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 2005;280:20589-95. (Pubitemid 40776761)
40. Ulrich S, Loitsch SM, Rau O, von Knethen A, Brune B, Schubert-Zsilavecz M, et al. Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res 2006;66:7348-54. (Pubitemid 44197718)
41. Ouyang W, Beckett O, Ma Q, Paik J-h, DePinho RA, Li MO. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat Immunol 2010;11:618-27.
42. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006;55: 2180-91. (Pubitemid 44743614)
43. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 2007;104:7217-22. (Pubitemid 47186035)
44. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 2007;104:12017-22. (Pubitemid 47185622)
45. Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, et al. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 2004;12:5571-8. (Pubitemid 39304056)
46. Leiro J, Alvarez E, Arranz JA, Laguna R, Uriarte E, Orallo F. Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J Leukoc Biol 2004;75:1156-65. (Pubitemid 38720660)
47. Gehm BD, McAndrews JM, Chien P-Y, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. PNAS 1997;94:14138-43. (Pubitemid 28009723)
48. Rosenberg GA. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 2002;8:586-95. (Pubitemid 35379453)
49. Hafler DA, Weiner HL. MS: a CNS and systemic autoimmune disease. Immunol Today 1989;10:104-7. (Pubitemid 19087467)
50. Hafler DA, Weiner HL. T cells in multiple sclerosis and inflammatory central nervous system diseases. Immunol Rev 1987;100:307-32. (Pubitemid 18017646)
51. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104:182-91. (Pubitemid 34792722)
52. Weiner HL, Hafler DA, Fallis RJ, Johnson D, Ault KA, Hauser SL. T cell subsets in patients with multiple sclerosis. An overview. Ann NY Acad Sci 1984;436:281-93.
53. Rasmussen S, Wang Y, Kivisakk P, Bronson RT, Meyer M, Imitola J, et al. Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing-remitting experimental autoimmune encephalomyelitis. Brain 2007;130:2816-29. (Pubitemid 350033966)
54. Calabresi PA, Fields NS, Farnon EC, Frank JA, Bash CN, Kawanashi T, et al. ELI-spot of Th-1 cytokine secreting PBMC's in multiple sclerosis: correlation with MRI lesions. J Neuroimmunol 1998;85:212-9. (Pubitemid 28313506)
55. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990;8:579-621. (Pubitemid 20135640)
56. Bernard CC, Carnegie PR. Experimental autoimmune encephalomyelitis in mice: immunologic response to mouse spinal cord and myelin basic proteins. J Immunol 1975;114:1537-40.
57. Kuchroo VK, Anderson AC, Waldner H, Munder M, Bettelli E, Nicholson LB. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol 2002;20:101-23. (Pubitemid 34293422)
58. Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, Marusic S. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007;178:2589-98. (Pubitemid 46233462)
59. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005;11:335-9. (Pubitemid 40460563)
60. Linthicum DS, Frelinger JA. Acute autoimmune encephalomyelitis in mice. II. Susceptibility is controlled by the combination of H-2 and histamine sensitization genes. J Exp Med 1982;156:31-40. (Pubitemid 12082485)
61. Vaknin-Dembinsky A, Balashov K, Weiner HL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 2006;176:7768-74. (Pubitemid 43849078)
62. Li Y, Chu N, Hu A, Gran B, Rostami A, Zhang G-X. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 2007;130:490-501. (Pubitemid 46181102)
63. Woodroofe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 1993;5: 583-8. (Pubitemid 24072061)
64. Schonrock LM, Gawlowski G, Brück W. Interleukin-6 expression in human multiple sclerosis lesions. Neurosci Lett 2000;294:45-8.
65. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101-4. (Pubitemid 29186827)
66. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Genemicroarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500-8. (Pubitemid 34546753)
67. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006;177:566-73. (Pubitemid 43939170)
68. Okuda Y, Sakoda S, Fujimura H, Saeki Y, Kishimoto T, Yanagihara T. IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glycoprotein 35-55 induced experimental autoimmune encephalomyelitis. J Neuroimmunol 1999;101:188-96. (Pubitemid 29516459)
69. Samoilova EB, Horton JL, Hilliard B, Liu T-ST, Chen Y. IL-6-deficientmice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol 1998;161:6480-6. (Pubitemid 28562184)
70. Woltman AM, de Haij S, Boonstra JG, Gobin SJ, Daha MR, van Kooten C. Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol 2000;11:2044-55.
71. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human T(H)17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007;13:1173-5. (Pubitemid 47530640)
72. Tsaknaridis L, Spencer L, Culbertson N, Hicks K, LaTocha D, Chou YK, et al. Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res 2003;74:296-308. (Pubitemid 37193716)
73. Carlson T, Kroenke M, Rao P, Lane TE, Segal B. The Th17-ELR + CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med 2008;205:811-23.
74. Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem 1998;273:27467-73. (Pubitemid 28500465)
75. JovanovicDV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-{beta} and TNF-{alpha}, by human macrophages. J Immunol 1998;160:3513-21. (Pubitemid 28164746)
76. Kawanokuchi J, Shimizu K, Nitta A, Yamada K, Mizuno T, Takeuchi H, et al. Production and functions of IL-17 in microglia. J Neuroimmunol 2008;194:54-61.
77. Ma X, Reynolds SL, Baker BJ, Li X, Benveniste EN, Qin H. IL-17 enhancement of the IL-6 signaling cascade in astrocytes. J Immunol 2010;184:4898-906.
78. Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, Nomura S, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci 2008;105:9041-6.
79. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4 + CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6. (Pubitemid 36222922)
80. Wan S, Xia C, Morel L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4 + CD25+ T cell regulatory functions. J Immunol 2007;178:271-9. (Pubitemid 46033610)
81. Doganci A, Eigenbrod T, Krug N, De Sanctis GT, Hausding M, Erpenbeck VJ, et al. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest 2005;115: 313-25. (Pubitemid 40385473)
82. Dominitzki S, Fantini MC, Neufert C, Nikolaev A, Galle PR, Scheller J, et al. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4 + CD25 T cells. J Immunol 2007;179:2041-5.
83. Okada S, MN, Mikami Y, Shimazaki T, Mihara M, Ohsugi Y, Iwamoto Y, et al. Blockade of interleukin-6 receptor suppresses reactive astrogliosis andameliorates functional recovery in experimental spinal cord injury. J Neurosci Res 2004;76:265-76. (Pubitemid 38451214)
84. Samuelsson A-M, Jennische E, Hansson H-A, Holmang A. Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABAA dysregulation and impaired spatial learning. Am J Physiol Regul Integr Comp Physiol 2006;290:R1345-56.
85. Balasingam V, Tejada-Berges T, Wright E, Bouckova R, Yong VW. Reactive astrogliosis in the neonatalmouse brain and itsmodulation by cytokines. J Neurosci 1994;14:846-56. (Pubitemid 24043936)
86. Okada S, Nakamura M, Mikami Y, Shimazaki T, Mihara M, Ohsugi Y, et al. Blockade of interleukin-6 receptor suppresses reactive astrogliosis and ameliorates functional recovery in experimental spinal cord injury. J Neurosci Res 2004;76:265-76. (Pubitemid 38451214)
87. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32. (Pubitemid 41541790)
88. Kleinschek MA, Owyang AM, Joyce-Shaikh B, Langrish CL, Chen Y, Gorman DM, et al. IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med 2007;204:161-70. (Pubitemid 46148766)
89. Pahan K, Sheikh FG, Liu X, Hilger S, McKinney M, Petro TM. Induction of nitricoxide synthase and activation of NF-kappaB by interleukin-12 p40 in microglial cells. J Biol Chem 2001;276:7899-905.
90. Mondal S, Roy A, Pahan K. Functional blocking monoclonal antibodies against IL-12p40 homodimer inhibit adoptive transfer of experimental allergic encephalomyelitis. J Immunol 2009;182:5013-23, doi:10.4049/jimmunol.0801734.
91. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 2008;205:1535-41. (Pubitemid 351962016)
92. Segal BM, Shevach EM. IL-12 unmasks latent autoimmune disease in resistant mice. J Exp Med 1996;184:771-5. (Pubitemid 26324133)
93. Venken K, Hellings N, Thewissen M, Somers V, Hensen K, Rummens J, et al. Compromised CD4+;CD25high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 2008;123:79-89. (Pubitemid 350255996)
94. Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005;81: 45-52. (Pubitemid 41139109)
95. Stephens LA, Malpass KH, Anderton SM. Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg. Eur J Immunol 2009;39:1108-17.
96. Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 2007;8:1380-9. (Pubitemid 350131175)
97. Fitzgerald DC, Zhang GX, El-Behi M, Fonseca-Kelly Z, Li H, Yu S, et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007;8:1372-9. (Pubitemid 350131174)
98. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007;8:1390-7. (Pubitemid 350138974)
99. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-9. (Pubitemid 350190247)
100. Stern JNH, Keskin DB, Zhang H, Lv H, Kato Z, Strominger JL. Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice. Proc Natl Acad Sci USA 2008;105:5172-6. (Pubitemid 351738529)
101. Stern JNH, Zsolt I, Reddy J, Keskin DB, Sheu E, Fridkis-Hareli M, et al. Amelioration of proteolipid protein 139â€"151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms. Proc Natl Acad Sci USA 2004;101:11743-8.
102. Aharoni R, Eilam R, Stock A, Vainshtein A, Shezen E, Gal H, Friedman N, Arnon R, et al. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. J of Neuroimmunol 2010;225:100-11.
103. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005;102:6449-54. (Pubitemid 40617463)
104. Haas J, Korporal M, Balint B, Fritzsching B, Schwarz A, Wildemann B.Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4 + CD25 + FOXP3 + CD31+ T-cells in patients with multiple sclerosis. J Neuroimmunol 2009;216:113-7.
105. Vinod SR, Markovic-Plese S. Interferon - beta inhibits Th17 cell differentiation in patients with multiple sclerosis. Endocr Metab Immune Disord Drug Targets 2010;10:161.
106. Vandenbark AA, Huan J, Agotsch M, La Tocha D, Goelz S, Offner H, et al. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4 + CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 2009;215: 125-8.
107. Namdar A, Nikbin B, Ghabaee M, Bayati A, Izad M. Effect of IFN-β therapy on the frequency and function of CD4+CD25+ regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. J Neuroimmunol 2010;218:120-4.
108. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, de Waal Malefyt R, Steinman L, Raman C, et al. T helper type 1 and 17 cells determine efficacy of interferon-[beta] in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16:406-12.
109. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Investig 2008;118:1680-90. (Pubitemid 351632372)
110. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996;184:387-96. (Pubitemid 26324092)
111. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61. (Pubitemid 36222930)
112. Xiao S, Jin H, Korn T, Liu SM, Oukka M, Lim B, et al. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-{beta}-driven Smad3 signaling and Inhibiting IL-6 and IL-23 receptor expression. J Immunol 2008;181:2277-84.
113. Yamashita H, ten Dijke P, Franzén P, Miyazono K, Heldin CH. Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-beta. J Biol Chem 1994;269:20172-8.
114. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier J-M. Direct binding of Smad3 and Smad4 to critical TGF[beta]-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998;17:3091-100.
115. Mantel P-Y, Ouaked N, Ruckert B, Karagiannidis C, Welz R, Blaser K, et al. Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol 2006;176:3593-602. (Pubitemid 43364007)
116. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2008;9:194-202.
117. Pallandre JR, Brillard E, Crehange G, Radlovic A, Remy-Martin JP, Saas P, et al. Role of STAT3 in CD4 + CD25 + FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. J Immunol 2007;179:7593-604.
118. Mizutani K, Ikeda K, Yamori Y. Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun 2000;274:61-7. (Pubitemid 30496757)
119. Chavez E, Reyes-Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Vergara P, et al. Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCl4 treatment in rats. J Appl Toxicol 2008;28:35-43.
120. Serrero G, Lu R. Effect of resveratrol on the expression of autocrine growth modulators in human breast cancer cells. Antioxid Redox Signal 2001;3:969-79. (Pubitemid 34027357)
121. Suenaga F, Hatsushika K, Takano S, Ando T, Ohnuma Y, Ogawa H, et al. A possible link between resveratrol and TGF-beta: resveratrol induction of TGF-beta expression and signaling. FEBS Lett 2008;582:586-90.
122. Zhang J, Lee SM, Shannon S, Gao B, Chen W, Chen A, et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 2009;119:3048-58.
123. Nie Y, Erion DM, Yuan Z, Dietrich M, Shulman GI, Horvath TL, Gao Q. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol 2009;11: 492-500.
124. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994;24:1434-40. (Pubitemid 24169530)
125. Fiorentino D, Zlotnik A, Mosmann T, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-22.
126. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081-95.
127. Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996;45:322-33. (Pubitemid 26299587)
128. van Boxel-Dezaire AH, Hoff SC, van Oosten BW, Verweij CL, Drager AM, Ader HJ, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 1999;45:695-703. (Pubitemid 29260746)
129. Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR. Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis. J Neuroimmunol 2004;146: 209-15. (Pubitemid 38032974)
130. Diab A, Zhu J, Xiao BG, Mustafa M, Link H. High IL-6 and low IL-10 in the central nervous system are associated with protracted relapsing EAE in DA rats. J Neuropathol Exp Neurol 1997;56:641-50. (Pubitemid 27463099)
131. Mathisen PM, Yu M, Johnson JM, Drazba JA, Tuohy VK. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J Exp Med 1997;186:159-64. (Pubitemid 27304859)
132. Yang JS, Xu LY, Huang YM, Van Der Meide PH, Link H, Xiao BG. Adherent dendritic cells expressing high levels of interleukin-10 and low levels of interleukin-12 induce antigen-specific tolerance to experimental autoimmune encephalomyelitis. Immunology 2000;101:397-403.
133. Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA, Kuchroo VK. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol 1998;161:3299-306.
134. Samoilova EB, Horton JL, Chen Y. Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice: roles of interleukin-10 in disease progression and recovery. Cell Immunol 1998;188:118-24. (Pubitemid 28493564)
135. Cua DJ, Groux H, Hinton DR, Stohlman SA, Coffman RL. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J Exp Med 1999;189:1005-10. (Pubitemid 29149357)
136. Cohen SJ, Cohen IR, Nussbaum G. IL-10 mediates resistance to adoptive transfer experimental autoimmune encephalomyelitis in MyD88(-/-) mice. J Immunol 2010;184:212-21.
137. Maron R, Hancock WW, Slavin A, Hattori M, Kuchroo V, Weiner HL. Genetic susceptibility or resistance to autoimmune encephalomyelitis in MHC congenic mice is associated with differential production of pro- and anti-inflammatory cytokines. Int Immunol 1999;11:1573-80. (Pubitemid 29425748)
138. Cannella B, Gao YL, Brosnan C, Raine CS. IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J Neurosci Res 1996;45:735-46. (Pubitemid 26332561)
139. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46. (Pubitemid 37328691)
140. Foey AD, Feldmann M, Brennan FM. Route of monocyte differentiation determines their cytokine production profile: CD40 ligation induces interleukin 10 expression. Cytokine 2000;12:1496-505.
141. Cao S, Zhang X, Edwards JP, Mosser DM. NF-{kappa}B1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem 2006;281:26041-50.
142. Wessells J, Baer M, Young HA, Claudio E, Brown K, Siebenlist U, et al. BCL-3 and NF-kB p50 attenuate lipopolysaccharide-induced inflammatory responses
143. Brenner S, Prösch S, Schenke-Layland K, Riese U, Gausmann U, Platzer C. cAMP-induced interleukin-10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation. J Biol Chem 2003;278:5597-604. (Pubitemid 36800801)
144. Cao S, Liu J, Song L, Ma X. The protooncogene c-Maf is an essential transcription factor for IL-10 gene expression in macrophages. J Immunol 2005;174:3484-92. (Pubitemid 40354056)
145. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, de Waal Malefyt R, Rennick R, Kastelein RA, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002;16:779-90.
146. Yoshida H, Nakaya M, Miyazaki Y. Interleukin 27: a double-edged sword for offense and defense. J Leukoc Biol 2009;86:1295-303.
147. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007;8:1363-71. (Pubitemid 350131173)
148. Pot C, Jin H, Awasthi A, Liu SM, Lai C-Y, Madan R, et al. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J Immunol 2009;183:797-801.
149. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000;141:3657-67.
150. Levenson AS, Gehm BD, Pearce ST, Horiguchi J, Simons LA, Ward III JE. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha. Int J Cancer 2003;104:587-96. (Pubitemid 36337258)
151. Casper RF, Quesne M, Rogers IM, Shirota T, Jolivet A, Milgrom E, et al. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 1999;56:784-90. (Pubitemid 29491181)
152. Ciolino HP, Daschner PJ, Yeh GC. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 1998;58:5707-12. (Pubitemid 29006410)
153. Subramanian S, Matejuk A, Zamora A, Vandenbark AA, Offner H. Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system. J Immunol 2003;170:1548-55. (Pubitemid 36139527)
154. Tiwari-Woodruff S, Voskuhl RR. Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice. J Neuro Sci 2009;286:81-5.
155. Polanczyk MJ, Hopke C, Vandenbark AA, Offner H. Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res 2006;84:370-8. (Pubitemid 44126289)
156. Offner H, Adlard K, Zamora A, Vandenbark AA. Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis. J Clin Invest 2000;105:1465-72. (Pubitemid 30322412)
157. Soldan SS, Retuerto AIA, Sicotte NL, Voskuhl RR. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol 2003;171:6267-74. (Pubitemid 37467250)
158. Green S. Modulation of oestrogen receptor activity by oestrogens and antioestrogens. J Steroid Biochem Mol Biol 1990;37:747-51.
159. Freedman LP, Luisi BF. On the mechanism of DNA binding by nuclear hormone receptors: a structural and functional perspective. J Cell Biochem 1993;51: 140-50. (Pubitemid 23058570)
160. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. Nucl Recept Signal 2008;6:e003.
161. Dai R, Phillips RA, Ahmed SA. Despite inhibition of nuclear localization of NF-{kappa}B p65, c-Rel, and RelB, 17-beta estradiol up-regulates NF-{kappa}B signaling in mouse splenocytes: the potential role of Bcl-3. J Immunol 2007;179: 1776-83.
162. Polanczyk MJ, Carson BD, Subramanian S, Afentoulis M, Vandenbark AA, Ziegler SF, et al. Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol 2004;173:2227-30. (Pubitemid 39063075)
163. Polanczyk MJ, Hopke C, Huan J, Vandenbark AA, Offner H. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J Neuroimmunol 2005;170:85-92. (Pubitemid 41740909)
164. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 2008;105:9721-6. (Pubitemid 352031367)
165. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, et al. Control of T (reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008;453:65-71. (Pubitemid 351630328)
166. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 2008;105(28):9721-6. (Pubitemid 352031367)
167. Marshall NB, Vorachek WR, Steppan LB, Mourich DV, Kerkvliet NI. Functional characterization and gene expression analysis of CD4+ CD25+ regulatory T cells generated in mice treated with 2, 3, 7, 8-tetrachlorodibenzo- p-dioxin. J Immunol 2008;181:2382-91.
168. Perdew GH, Bradfield CA. Mapping the 90 kDa heat shock protein binding region of the Ah receptor. Biochem Mol Biol Int 1996;39:589-93. (Pubitemid 26254606)
169. Sogawa K, Fujii-Kuriyama Y. Ah receptor, a novel ligand-activated transcription factor. J Biochem 1997;122:1075-9. (Pubitemid 28019968)